Recently, Meinian Onehealth Healthcare Holdings Co.,Ltd. (002044.SZ, hereinafter referred to as "Meinian Onehealth") through its wholly-owned subsidiary Meinian Onehealth Industry (Group) Co., Ltd., signed a "Digital Asset Business Cooperation Framework Agreement" with GOFINTECH QUANT (00290.HK) and Northking Information Technology Co.,Ltd. (002987.SZ). The three parties will leverage their respective resource advantages to conduct comprehensive business exploration and cooperation in the digital asset RWA field, exploring new paradigms for releasing the value of equipment and data assets in the healthcare and medical sectors, and facilitating the upgrade and innovative development of the great health industry.
This collaboration builds upon Meinian Onehealth's core advantages in equipment assets, data assets, AI and other emerging technology digital asset applications. Under compliance with the digital asset regulatory frameworks of mainland China and Hong Kong, the parties will advance the exploration of medical asset RWA tokenization, promote the restructuring of asset value chains in the medical and healthcare fields, while leveraging RWA innovation models to unlock potential asset values and create new growth opportunities for Meinian Onehealth.
**Multi-dimensional Assets Foundation: Meinian Onehealth Deepens Core Moat in Medical Digitalization**
As a leading enterprise in China's health examination industry and a pioneer in real-world data platform construction, Meinian Onehealth has established differentiated competitive advantages in three major areas: equipment assets, data assets, and AI health management scenario applications, leveraging its nationwide medical service network, massive high-quality data reserves, and AI technology applications.
In terms of equipment assets, as of 2024, Meinian Onehealth's 576 health examination centers nationwide are equipped with large-scale medical equipment matrices including MRI and CT scanners. The equipment ownership is clear and revenues are stable and quantifiable, forming a solid foundation of physical assets. In the data asset dimension, the company has cumulatively served over 200 million person-times, with health examination services exceeding 25 million person-times in 2024, accumulating multi-modal health data covering examination indicators, imaging records, and lifestyle patterns. The company has established scientific research cooperation with multiple universities, research institutions, and renowned pharmaceutical companies, and has continuously published the "Meinian Health Annual Health Examination Big Data Blue Book" for multiple years. Both data coverage breadth and commercial application potential are industry-leading.
In AI applications, Meinian Onehealth has deployed AI intelligent agents and AI health management systems, with scenario-based applications including the digital health management assistant "Health Xiao Mei," intelligent chief examination doctors, and blood sugar management assistant "Tang Dou," gradually building a multi-intelligent agent service platform for chronic disease management. Through AI algorithms for deep mining of structured health examination data, the system can generate dynamic health portraits, disease risk prediction models, and other high-value outputs, potentially providing technical support for insurance company underwriting and pharmaceutical company real-world studies, continuously expanding the service boundaries of health management.
Meinian Onehealth's data and AI capabilities will jointly constitute a future-oriented, high-value real-world research service platform, capable of providing high-value data insights and technical services to pharmaceutical companies, research institutions, and other clients in key areas such as new drug development, clinical trial acceleration (especially in patient recruitment), and post-market studies, forming clear and sustainable business models. Such predictable stable future revenues serve as important support for the value of digital assets like "data authorization revenue rights."
**RWA Empowerment: Creating New Ecosystem for Global Circulation and Value Growth of Medical Assets**
According to the agreement, Meinian Onehealth, GOFINTECH QUANT, and Northking Information Technology will use the revenue rights of Meinian Onehealth's equipment assets, data assets, AI and other emerging technology digital assets as underlying assets to jointly conduct digital rights confirmation and RWA tokenization exploration. Initially, they plan to pilot with revenue rights of large medical equipment as underlying assets, subsequently planning to gradually expand to data authorization revenue rights and AI and other emerging digital asset revenue rights. This is expected to activate existing asset values, realize equipment asset monetization and data asset liquidity, assist the company's strategic transformation from "health examination service provider" to "medical data technology platform," and complete the "data generation-asset rights confirmation-value realization" closed loop, demonstrating the commercial potential of Meinian Onehealth's data and AI technology.
GOFINTECH QUANT and Northking Information Technology will also leverage their technical resources and market resources to promote the issuance of Meinian Onehealth RWA tokens and help introduce more potential investors such as research institutions and pharmaceutical companies. Together, they will leverage blockchain characteristics to enhance Meinian Onehealth's data rights confirmation capabilities, asset liquidity capabilities, and business expansion capabilities. Both parties will jointly explore achieving the goal of optimizing Meinian Onehealth's cash flow structure through tokenization while further enhancing Meinian Onehealth's data advantages and technological advantages.
**Underlying Asset Valuation Support: Meinian Onehealth's Implemented Technology and Cooperation Achievements**
The value of Meinian Onehealth's data and AI is not merely conceptual but has been implemented through multiple solid achievements, providing reliable basis for the valuation of RWA underlying assets.
1. **National Key R&D Program Project Implementation, Consolidating Data Asset Value**
In 2024, Meinian Onehealth led the completion of the National Key R&D Program project "Construction of Health Examination Big Data Cloud Platform," which completed the aggregation of health examination data from over 130 million person-times. This project not only helps enhance the value of data assets in the health examination industry and continuous training optimization of AI large models, providing important technical support for the transformation and upgrade of China's health examination industry, but also lays a solid foundation for Meinian's "All in AI" strategy. It also realizes further integration of health examination and medical data, helping to build users' full life-cycle health records, providing robust data foundation for precision medicine research and intelligent health management, with important significance for improving national health levels and promoting Healthy China construction.
2. **AI Application Scenario Implementation, Strengthening Technical Asset Value**
Under the empowerment of large model technology and AI Agent intelligent agents, Meinian Onehealth has deployed multiple scenario-based applications, including the digital health management assistant "Health Xiao Mei," intelligent chief examination doctors, and blood sugar management assistant "Tang Dou," gradually building a multi-intelligent agent service platform for chronic disease management. In the future, as Meinian's user data continues to accumulate and expert experience builds up, creating business flywheel effects, these intelligent agents will also undergo algorithmic optimization, gradually self-learning and evolving, further empowering Meinian Onehealth's business cost reduction, efficiency improvement, and health management services. Their technical service revenues will become an important component of AI asset revenue rights.
3. **Continuous Output of Health Big Data Research Results, Validating Data Commercial Potential**
Meinian Onehealth has jointly published the "Meinian Health Annual Health Examination Big Data Blue Book" with Peking University Health Science Center for multiple consecutive years. Based on annual health examination samples from tens of millions of people, covering 31 provinces, autonomous regions, and municipalities nationwide except Hong Kong, Macao, and Taiwan, with working-age population as the main analysis target (in the 2024 Blue Book, working-age population aged 25-59 accounts for 81.3%), it focuses on reflecting the health status of China's working-age population. This represents the most comprehensive health population examination data research in terms of examination population numbers and geographical coverage to date, potentially providing authoritative data reference for pharmaceutical companies' real-world studies and insurance companies' health risk assessments. The company has established research cooperation with multiple universities, research institutions, and renowned pharmaceutical companies. The business model of data authorization and research services has been preliminarily validated, providing actual cooperation case support for the valuation of data authorization revenue rights.
**Data Differentiation Advantages Highlighted: Health Examination Data Becomes Scarce Resource in Research and Commercial Scenarios**
In the medical and healthcare field, data value depends on its scarcity and application scenarios, and Meinian Onehealth's health examination data is becoming a scarce resource in research and commercial fields with three unique advantages.
**(1) Population Characteristics Advantage**
**Forward-looking value focusing on healthy populations.** The core advantage of health examination data lies in its coverage of asymptomatic healthy or sub-healthy populations. This population characteristic has unique research value—it shifts medical research focus from "already ill" to "not yet ill," from disease treatment to disease prevention. In Meinian Onehealth's examination population, the vast majority of examinees have no obvious clinical symptoms at the time of examination, providing a valuable data window for early disease identification and intervention.
**Breaking through limitations of traditional medical data.** Traditional hospital data mainly comes from patient populations who have already developed diseases. While such data has important value for disease diagnosis and treatment, it has obvious limitations in disease prevention and early intervention. Hospital data often records mid-to-late stages of disease development, lacking key information from the transformation process between healthy states and disease states. Health examination data precisely fills this gap, capturing early signals of disease occurrence and development and trajectory changes in subclinical stages.
**(2) Data Richness Advantage**
**Professional advantage of medical-grade detection accuracy.** Compared to consumer-grade health monitoring hardware such as wearable devices, health examination data has medical-grade detection accuracy and professional clinical significance. While wearable devices can provide continuous physiological parameter monitoring, their detection accuracy and clinical value are relatively limited. Health examination data comes from professional medical equipment and standardized testing processes, with higher data quality and clinical value, making it more suitable for serious medical research.
**Comprehensive multi-modal data fusion.** Compared to single examinations, health examinations provide comprehensive data covering multiple dimensions including imaging, biochemical testing, physiological indicators, and genetic testing. This multi-modal data fusion can construct more comprehensive individual health portraits, providing richer information foundation for disease risk assessment and health status evaluation.
**(3) Cohort Study Advantage**
**Natural cohort tracking mechanism.** Health examination data has unique advantages in cohort studies. Annual health examinations themselves constitute a natural follow-up mechanism, with routine annual examinations forming standardized data collection points. This natural cohort characteristic avoids complex follow-up design and implementation challenges in traditional cohort studies, providing an ideal data collection platform for long-term cohort research.
**High compliance guaranteed by enterprise group examinations.** A large portion of Meinian Onehealth's services comes from enterprise group health examinations, and this service model ensures high follow-up compliance. Annual health examinations for enterprise employees often have institutional characteristics with relatively low employee turnover rates, providing important guarantees for constructing long-term stable cohorts.
These unique advantages have been transformed into substantial research achievements, supporting both cross-sectional and longitudinal cohort studies that have contributed to major research projects and scientific publications. The company has participated in national-level research projects, published numerous high-impact scientific papers, and established productive industry-academia-research partnerships.
Based on these high-value assets and solid achievements, the RWA cooperation between Meinian Onehealth, GOFINTECH QUANT, and Northking Information Technology is not simply "asset tokenization" but rather "deep transformation from assets to value."
**About GOFINTECH QUANT:** GOFINTECH QUANT (00290.HK) is a cross-border and cross-sector technology innovation investment platform based in Hong Kong, backed by the Greater Bay Area, and facing the international market. It holds licenses 1, 4, 6, and 9 issued by the Securities and Futures Commission of Hong Kong, as well as cross-border QFII, CIBM, QDIE, QFLP, and Bond Connect business qualifications. The company has constructed an ecological closed loop of four major business sectors: technology innovation + finance + arts + trade, with substantial strategic deployment in frontier technology fields such as quantum technology and digital assets, becoming a global innovation leader in quantum technology applications.
**About Northking Information Technology:** Northking Information Technology Co.,Ltd. [Stock Code: 002987] is a leading domestic provider of intelligent technology and fintech services, committed to providing comprehensive, high-quality software products and information technology solutions and services to help clients achieve comprehensive digital transformation. Based on next-generation information technologies such as artificial intelligence, big data, cloud computing, blockchain, privacy computing, and digital twins, deeply integrated with long-term industry knowledge accumulation, the company has constructed a complete business system covering artificial intelligence and big data innovation products, fintech solutions, and digital operation of software development and service businesses. As of the end of 2024, the company has maintained long-term stable cooperative relationships with over 550 legal person institutions, including over 400 legal person financial institutions, covering fifteen types of licensed financial institutions including banks, insurance companies, and securities firms.
**About Meinian Onehealth:** Meinian Onehealth Healthcare Holdings Co.,Ltd. (A-share: SZ002044) was founded in 2004 and listed on the Shenzhen Main Board in 2015. It is a health examination and medical group with significant scale and influence in China. Meinian Onehealth Group takes health examination as its core business, integrating health consultation, health assessment, and health management. Relying on nationwide network layout, millions of customer base, massive health big data, and standardized medical health service systems, the company provides high-quality health management services to enterprise and individual clients in areas such as professional prevention, disease screening, chronic disease management, and medical concierge services. The company actively embraces the digitalized and intelligent medical era, leading the upgrade of health examination models and health service formats through innovation in four aspects: technology, products, services, and management. It extensively applies artificial intelligence technology and adheres to empowering comprehensive, full life-cycle health management services for clients through digitalized operations.
**Risk Warning:** The above content currently does not constitute any impact on the company's operating performance. Investors are advised to pay attention to investment risks!